ACET Valuation

Adicet Bio Inc

Add to Watchlist

Advanced Chart

0.730

-0.004(-0.545%)1D

Overview
Forecast
Valuation
Earnings

ACET Relative Valuation

ACET's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACET is overvalued; if below, it's undervalued.

Historical Valuation

Adicet Bio Inc (ACET) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.48. The fair price of Adicet Bio Inc (ACET) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：0.75

Fair

-0.62

Trailing

Forward

0.00

EV/EBITDA

Adicet Bio Inc. (ACET) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.67. The thresholds are as follows: Strongly Undervalued below -4.31, Undervalued between -4.31 and -2.49, Fairly Valued between 1.14 and -2.49, Overvalued between 1.14 and 2.96, and Strongly Overvalued above 2.96. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.41

EV/EBIT

Adicet Bio Inc. (ACET) has a current EV/EBIT of 0.41. The 5-year average EV/EBIT is -1.62. The thresholds are as follows: Strongly Undervalued below -6.93, Undervalued between -6.93 and -4.28, Fairly Valued between 1.03 and -4.28, Overvalued between 1.03 and 3.69, and Strongly Overvalued above 3.69. The current Forward EV/EBIT of 0.41 falls within the Historic Trend Line -Fairly Valued range.

0.00

Adicet Bio Inc. (ACET) has a current PS of 0.00. The 5-year average PS is 51.15. The thresholds are as follows: Strongly Undervalued below -150.44, Undervalued between -150.44 and -49.64, Fairly Valued between 151.94 and -49.64, Overvalued between 151.94 and 252.73, and Strongly Overvalued above 252.73. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.68

P/OCF

Adicet Bio Inc. (ACET) has a current P/OCF of -0.68. The 5-year average P/OCF is -14.08. The thresholds are as follows: Strongly Undervalued below -91.60, Undervalued between -91.60 and -52.84, Fairly Valued between 24.68 and -52.84, Overvalued between 24.68 and 63.43, and Strongly Overvalued above 63.43. The current Forward P/OCF of -0.68 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Adicet Bio Inc. (ACET) has a current P/FCF of 0.00. The 5-year average P/FCF is -5.50. The thresholds are as follows: Strongly Undervalued below -17.68, Undervalued between -17.68 and -11.59, Fairly Valued between 0.60 and -11.59, Overvalued between 0.60 and 6.69, and Strongly Overvalued above 6.69. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Adicet Bio Inc (ACET) has a current Price-to-Book (P/B) ratio of 0.46. Compared to its 3-year average P/B ratio of 0.72 , the current P/B ratio is approximately -36.04% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about -59.36% higher. Adicet Bio Inc (ACET) has a Forward Free Cash Flow (FCF) yield of approximately -167.25%. Compared to its 3-year average FCF yield of -90.48%, the current FCF yield is approximately 84.85% lower. Relative to its 5-year average FCF yield of -59.83% , the current FCF yield is about 179.56% lower.

0.46

P/B

Median3y

0.72

Median5y

1.13

-167.25

FCF Yield

Median3y

-90.48

Median5y

-59.83

Competitors Valuation Multiple

The average P/S ratio for ACET's competitors is 10.51, providing a benchmark for relative valuation. Adicet Bio Inc Corp (ACET) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Werewolf Therapeutics Inc

Karyopharm Therapeutics Inc

PDS Biotechnology Corp

Loss

58.29M

SLGL.O

Sol Gel Technologies Ltd

8.25

217.71%

66.02M

Performance Decomposition

Market capitalization of ACET increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ACET in the past 1 year is driven by Unknown.